標題: Titlebook: Biopharmaceutical Drug Design and Development; Susanna Wu-Pong (Director),Yon Rojanasakul (Profes Book 2008Latest edition Humana Press 200 [打印本頁] 作者: 掩飾 時間: 2025-3-21 16:17
書目名稱Biopharmaceutical Drug Design and Development影響因子(影響力)
書目名稱Biopharmaceutical Drug Design and Development影響因子(影響力)學(xué)科排名
書目名稱Biopharmaceutical Drug Design and Development網(wǎng)絡(luò)公開度
書目名稱Biopharmaceutical Drug Design and Development網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Biopharmaceutical Drug Design and Development被引頻次
書目名稱Biopharmaceutical Drug Design and Development被引頻次學(xué)科排名
書目名稱Biopharmaceutical Drug Design and Development年度引用
書目名稱Biopharmaceutical Drug Design and Development年度引用學(xué)科排名
書目名稱Biopharmaceutical Drug Design and Development讀者反饋
書目名稱Biopharmaceutical Drug Design and Development讀者反饋學(xué)科排名
作者: 可以任性 時間: 2025-3-21 23:32
Small Nucleic Acid-Based Drugs: Successes and Pitfalls,improved properties and mechanisms of action. RNA-based gene inhibitors have also powerfully merged onto the scene with first ribozymes, and now siRNA, providing new approaches to gene inhibition. This chapter will review the area of small nucleic acid drugs in terms of their design, delivery, and application.作者: 等級的上升 時間: 2025-3-22 02:09 作者: 惡意 時間: 2025-3-22 05:56 作者: ETCH 時間: 2025-3-22 10:43
Book 2008Latest editionery, stem cells, nucleic acid-based therapeutics, and macromolecular drug delivery. Authors also study pharmacogenetics in the clinic and changes in biologic drug approval at the FDA. Biopharmaceutical Drug Design and Development, Second Edition, is a worthy sequel to a discussion on the dynamic, exciting field of biotechnology..作者: BANAL 時間: 2025-3-22 13:25
https://doi.org/10.1007/978-3-540-45867-8 of scientific questions in the pharmaceutical industry, particularly in drug discovery and development. The technique has immense potential and promises to play a key role in furthering research in a number of fields, as discussed in this chapter.作者: 量被毀壞 時間: 2025-3-22 19:51 作者: 滑稽 時間: 2025-3-22 23:00
5.1 Fundamentals of diode lasers,political considerations, many methodological issues, such as choice of cell type, culture and differentiation methods, stability of cells in culture, and transplantation techniques, remain. This chapter reviews these issues and presents some novel potential applications.作者: 吹牛需要藝術(shù) 時間: 2025-3-23 02:48
https://doi.org/10.1007/978-3-642-56963-0improved properties and mechanisms of action. RNA-based gene inhibitors have also powerfully merged onto the scene with first ribozymes, and now siRNA, providing new approaches to gene inhibition. This chapter will review the area of small nucleic acid drugs in terms of their design, delivery, and application.作者: visceral-fat 時間: 2025-3-23 08:43
T. Kawaguchi,K. Hishida,M. Maedahe increasing number of examples of genetic polymorphisms affecting drug response in the literature, pharmacogenetic data are rarely used in current clinical practice. The limitations that have prevented the use of pharmacogenetic testing in clinical practice are reviewed.作者: Eclampsia 時間: 2025-3-23 12:22 作者: compel 時間: 2025-3-23 15:17 作者: osteocytes 時間: 2025-3-23 21:07
5.1 Fundamentals of diode lasers,l, and social implications of the project. The implications of the HGP on the current methods used in biomedical research and its impact on future healthcare are vast and far-reaching. This chapter reviews these topics and also provides a glimpse into the post-HGP era.作者: 擴大 時間: 2025-3-23 22:22
5.1 Fundamentals of diode lasers,cs are used for new gene identification, selection of genes or proteins that may be potential drug targets, and the screening of libraries, both in vitro and ., for designation of new lead drug compounds.作者: opportune 時間: 2025-3-24 04:07
Micron-Resolution Velocimetry Techniquesis also made to some of the challenges that lie at the cutting edge of these disciplines. We highlight a number of techniques and related software programs as they apply to the development of therapeutic pharmaceutical and biopharmaceutical agents.作者: 全等 時間: 2025-3-24 09:05
Biotechnology: 2008 and Beyond,ility to disease and their response to medications. Furthermore, new types of drugs that allow much more specific therapy for diseases and disorders with genetic components are in development. This chapter examines how the genomics era and biotechnology are changing biomedical science and health care.作者: 錢財 時間: 2025-3-24 11:36 作者: GRIN 時間: 2025-3-24 15:41
The Use of Bioinformatics and Chemogenomics in Drug Discovery,cs are used for new gene identification, selection of genes or proteins that may be potential drug targets, and the screening of libraries, both in vitro and ., for designation of new lead drug compounds.作者: 心痛 時間: 2025-3-24 20:05
Molecular Modeling: Considerations for the Design of Pharmaceuticals and Biopharmaceuticals,is also made to some of the challenges that lie at the cutting edge of these disciplines. We highlight a number of techniques and related software programs as they apply to the development of therapeutic pharmaceutical and biopharmaceutical agents.作者: arabesque 時間: 2025-3-25 03:05
https://doi.org/10.1007/978-3-540-45867-8ten empiric and reactive; the future of medicine will involve a detailed understanding of the role each individual’s genetics plays on their susceptibility to disease and their response to medications. Furthermore, new types of drugs that allow much more specific therapy for diseases and disorders w作者: fructose 時間: 2025-3-25 05:31
5.1 Fundamentals of diode lasers,r goals included sequencing other genomes, developing new related technology, making the technology widely accessible, and examining the ethical, legal, and social implications of the project. The implications of the HGP on the current methods used in biomedical research and its impact on future hea作者: 追逐 時間: 2025-3-25 10:08
5.1 Fundamentals of diode lasers,tabases are offering new avenues for the identification of novel genes and drug targets. This communication reviews how bioinformatics and chemogenomics are used for new gene identification, selection of genes or proteins that may be potential drug targets, and the screening of libraries, both in vi作者: 討好女人 時間: 2025-3-25 14:06 作者: lattice 時間: 2025-3-25 15:50
https://doi.org/10.1007/978-3-540-45867-8analysis. This chapter reviews the current status of protein microarray assays and highlights efforts using cells and tissues on microarrays. These ‘other’ microarrays have the potential to yield highly parallel miniaturized assays that will accelerate drug discovery efforts and facilitate understan作者: 供過于求 時間: 2025-3-25 22:52 作者: Merited 時間: 2025-3-26 03:54 作者: 芳香一點 時間: 2025-3-26 07:49 作者: BRUNT 時間: 2025-3-26 10:39
5.1 Fundamentals of diode lasers,apies or by identification of drugs using high-throughput stem cell cultures differentiated into specific mature cell types. This promising technology is based on isolation of pluripotent cells that can be expanded in culture and differentiated into a mature phenotype. In addition to the social and 作者: 不可接觸 時間: 2025-3-26 13:02 作者: 遺產(chǎn) 時間: 2025-3-26 20:27 作者: Instantaneous 時間: 2025-3-26 22:52
T. Kawaguchi,K. Hishida,M. Maedas may account for as much as 30% of interindividual differences in drug disposition and response. An increasing number of drug target polymorphisms have also been linked to differences in drug response. This chapter reviews some examples of the use of pharmacogenetics in clinical practice. Despite t作者: liaison 時間: 2025-3-27 03:13 作者: explicit 時間: 2025-3-27 07:41 作者: 可耕種 時間: 2025-3-27 10:10 作者: 龍蝦 時間: 2025-3-27 16:59
R. J. Adrian,D. F. G. Durao,J. H. Whitelaw no FOPP have yet been approved in the US or European pharmaceutical market. This is because of a lack of registration process for the demonstration of pharmaceutical and therapeutic/clinical equivalence. The production of FOPP is a significant opportunity for patients, managed health care providers作者: 高原 時間: 2025-3-27 18:04 作者: Defraud 時間: 2025-3-27 23:58
Microarray Technology Using Proteins, Cells, and Tissues,analysis. This chapter reviews the current status of protein microarray assays and highlights efforts using cells and tissues on microarrays. These ‘other’ microarrays have the potential to yield highly parallel miniaturized assays that will accelerate drug discovery efforts and facilitate understanding of biological complexity.作者: 有節(jié)制 時間: 2025-3-28 03:00 作者: 無脊椎 時間: 2025-3-28 06:50
http://image.papertrans.cn/b/image/188315.jpg作者: 要素 時間: 2025-3-28 13:54
https://doi.org/10.1007/978-3-540-45867-8analysis. This chapter reviews the current status of protein microarray assays and highlights efforts using cells and tissues on microarrays. These ‘other’ microarrays have the potential to yield highly parallel miniaturized assays that will accelerate drug discovery efforts and facilitate understanding of biological complexity.作者: flammable 時間: 2025-3-28 18:36 作者: neutral-posture 時間: 2025-3-28 20:16
The Human Genome Project and Drug Development,r goals included sequencing other genomes, developing new related technology, making the technology widely accessible, and examining the ethical, legal, and social implications of the project. The implications of the HGP on the current methods used in biomedical research and its impact on future hea作者: hedonic 時間: 2025-3-29 01:56
The Use of Bioinformatics and Chemogenomics in Drug Discovery,tabases are offering new avenues for the identification of novel genes and drug targets. This communication reviews how bioinformatics and chemogenomics are used for new gene identification, selection of genes or proteins that may be potential drug targets, and the screening of libraries, both in vi作者: 原告 時間: 2025-3-29 04:32 作者: adipose-tissue 時間: 2025-3-29 09:44
Microarray Technology Using Proteins, Cells, and Tissues,analysis. This chapter reviews the current status of protein microarray assays and highlights efforts using cells and tissues on microarrays. These ‘other’ microarrays have the potential to yield highly parallel miniaturized assays that will accelerate drug discovery efforts and facilitate understan作者: 在駕駛 時間: 2025-3-29 15:09
Pharmacogenetic Issues in Biopharmaceutical Drug Development,ted biotherapeutic molecules, make this an exciting era in personalized medicine. Pharmacogenetics, the term used to describe idiosyncratic responses to drug therapy having a genetic basis, has become much more than a few SNPs in some drug-metabolizing enzymes. With the advent of biopharmaceutical d作者: Headstrong 時間: 2025-3-29 19:14 作者: 培養(yǎng) 時間: 2025-3-29 23:23 作者: aesthetic 時間: 2025-3-30 00:19
Stem Cell Technology and Drug Development,apies or by identification of drugs using high-throughput stem cell cultures differentiated into specific mature cell types. This promising technology is based on isolation of pluripotent cells that can be expanded in culture and differentiated into a mature phenotype. In addition to the social and 作者: 雀斑 時間: 2025-3-30 06:21
Small Nucleic Acid-Based Drugs: Successes and Pitfalls,ve used this technique for functional genomics or to test these molecules as potential therapeutic agents. During this time, the field has evolved from simple phosphodiester oligonucleotide (ODN) binding to complementary mRNA in vitro, to the development of hundreds of chemically modified ODNs with 作者: B-cell 時間: 2025-3-30 09:40 作者: HEPA-filter 時間: 2025-3-30 12:41
Pharmacogenetics in the Clinic,s may account for as much as 30% of interindividual differences in drug disposition and response. An increasing number of drug target polymorphisms have also been linked to differences in drug response. This chapter reviews some examples of the use of pharmacogenetics in clinical practice. Despite t作者: 終點 時間: 2025-3-30 16:40
Molecular Modeling: Considerations for the Design of Pharmaceuticals and Biopharmaceuticals,r-assisted drug design (CADD) and at the same time present context with respect to the discovery, design, and development of therapeutic agents. Note is also made to some of the challenges that lie at the cutting edge of these disciplines. We highlight a number of techniques and related software pro作者: Obliterate 時間: 2025-3-30 21:08 作者: 江湖騙子 時間: 2025-3-31 02:34
Changes in Biologic Drug Approval at FDA,promote rationale drug development. The agency is dynamic, and whereas plans are in place that may provide some concept of the direction of future changes for both drug and biologics reviews, local and world events often cause a reactionary response at the FDA that is often unpredictable. What is cl作者: ALTER 時間: 2025-3-31 05:34
Follow-On Protein Products: The Age of Biogenerics?, no FOPP have yet been approved in the US or European pharmaceutical market. This is because of a lack of registration process for the demonstration of pharmaceutical and therapeutic/clinical equivalence. The production of FOPP is a significant opportunity for patients, managed health care providers作者: 要求比…更好 時間: 2025-3-31 09:43 作者: 匍匐 時間: 2025-3-31 15:00
Pharmacogenetic Issues in Biopharmaceutical Drug Development,e. By their very nature, many of the diseases in question are multigenic and do not lend themselves to simple pharmacogenetic analysis. Some key examples of these and other issues surrounding the use of genetic information to combat human diseases are presented.
